- Home
- PHAR vs SBR Comparison
PHAR vs SBR Comparison
Compare PHAR & SBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- SBR
- Stock Information
- Founded
- PHAR 1988
- SBR 1982
- Country
- PHAR Netherlands
- SBR United States
- Employees
- PHAR N/A
- SBR N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- SBR Oil & Gas Production
- Sector
- PHAR Health Care
- SBR Energy
- Exchange
- PHAR Nasdaq
- SBR Nasdaq
- Market Cap
- PHAR 951.7M
- SBR 1.1B
- IPO Year
- PHAR N/A
- SBR N/A
- Fundamental
- Price
- PHAR $13.14
- SBR $71.14
- Analyst Decision
- PHAR Strong Buy
- SBR
- Analyst Count
- PHAR 3
- SBR 0
- Target Price
- PHAR $30.00
- SBR N/A
- AVG Volume (30 Days)
- PHAR 11.0K
- SBR 50.8K
- Earning Date
- PHAR 11-06-2025
- SBR 01-01-0001
- Dividend Yield
- PHAR N/A
- SBR 7.64%
- EPS Growth
- PHAR N/A
- SBR N/A
- EPS
- PHAR N/A
- SBR 5.05
- Revenue
- PHAR $339,836,000.00
- SBR $77,682,730.00
- Revenue This Year
- PHAR $17.70
- SBR N/A
- Revenue Next Year
- PHAR $12.25
- SBR N/A
- P/E Ratio
- PHAR N/A
- SBR $13.94
- Revenue Growth
- PHAR 22.44
- SBR N/A
- 52 Week Low
- PHAR $7.31
- SBR $58.25
- 52 Week High
- PHAR $17.08
- SBR $84.39
- Technical
- Relative Strength Index (RSI)
- PHAR 42.37
- SBR 48.06
- Support Level
- PHAR $13.08
- SBR $69.04
- Resistance Level
- PHAR $14.10
- SBR $72.98
- Average True Range (ATR)
- PHAR 0.52
- SBR 1.66
- MACD
- PHAR -0.16
- SBR 0.36
- Stochastic Oscillator
- PHAR 0.00
- SBR 64.56
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About SBR Sabine Royalty Trust
Sabine Royalty Trust is an express trust which is formed to receive Sabine Corporation's royalty and mineral interests, including landowner's royalties, overriding royalty interests, minerals production payments and any other similar, non-participatory interests, in certain Royalty Properties. The trusts producing and proved undeveloped oil and gas royalty properties are located in Florida, Louisiana, Mississippi, New Mexico, Oklahoma, and Texas.